SARTORIUS STEDIM BIOTECH (56S1.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:56S1 - FR0013154002 - Common Stock
207.9 EUR
+1.2 (+0.58%)
Taking everything into account, 56S1 scores 4 out of 10 in our fundamental rating. 56S1 was compared to 19 industry peers in the Life Sciences Tools & Services industry. Both the profitability and the financial health of 56S1 get a neutral evaluation. Nothing too spectacular is happening here. 56S1 is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
56S1 had positive earnings in the past year.
In the past year 56S1 had a positive cash flow from operations.
56S1 had positive earnings in each of the past 5 years.
Each year in the past 5 years 56S1 had a positive operating cash flow.
1.2 Ratios
56S1's Return On Assets of 3.35% is on the low side compared to the rest of the industry. 56S1 is outperformed by 68.42% of its industry peers.
Looking at the Return On Equity, with a value of 6.54%, 56S1 is doing worse than 63.16% of the companies in the same industry.
56S1 has a Return On Invested Capital (5.94%) which is in line with its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for 56S1 is in line with the industry average of 9.26%.
The 3 year average ROIC (10.41%) for 56S1 is well above the current ROIC(5.94%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.35% | ||
| ROE | 6.54% | ||
| ROIC | 5.94% |
ROA(3y)7.81%
ROA(5y)9.13%
ROE(3y)17.3%
ROE(5y)20.06%
ROIC(3y)10.41%
ROIC(5y)14.57%
1.3 Margins
With a Profit Margin value of 8.96%, 56S1 perfoms like the industry average, outperforming 52.63% of the companies in the same industry.
56S1's Profit Margin has declined in the last couple of years.
The Operating Margin of 56S1 (16.63%) is comparable to the rest of the industry.
56S1's Operating Margin has declined in the last couple of years.
56S1 has a Gross Margin of 45.64%. This is in the better half of the industry: 56S1 outperforms 63.16% of its industry peers.
In the last couple of years the Gross Margin of 56S1 has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.63% | ||
| PM (TTM) | 8.96% | ||
| GM | 45.64% |
OM growth 3Y-22.38%
OM growth 5Y-9.98%
PM growth 3Y-24.01%
PM growth 5Y-17.3%
GM growth 3Y-6.9%
GM growth 5Y-3.53%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), 56S1 is creating some value.
56S1 has more shares outstanding than it did 1 year ago.
56S1 has more shares outstanding than it did 5 years ago.
56S1 has a better debt/assets ratio than last year.
2.2 Solvency
56S1 has an Altman-Z score of 4.46. This indicates that 56S1 is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of 56S1 (4.46) is better than 89.47% of its industry peers.
The Debt to FCF ratio of 56S1 is 6.84, which is on the high side as it means it would take 56S1, 6.84 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of 56S1 (6.84) is comparable to the rest of the industry.
A Debt/Equity ratio of 0.50 indicates that 56S1 is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.50, 56S1 perfoms like the industry average, outperforming 47.37% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 6.84 | ||
| Altman-Z | 4.46 |
ROIC/WACC0.64
WACC9.26%
2.3 Liquidity
A Current Ratio of 1.05 indicates that 56S1 should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.05, 56S1 is doing worse than 73.68% of the companies in the same industry.
A Quick Ratio of 0.50 indicates that 56S1 may have some problems paying its short term obligations.
The Quick ratio of 56S1 (0.50) is worse than 84.21% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.05 | ||
| Quick Ratio | 0.5 |
3. Growth
3.1 Past
56S1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 35.11%, which is quite impressive.
Measured over the past 5 years, 56S1 shows a small growth in Earnings Per Share. The EPS has been growing by 4.19% on average per year.
Looking at the last year, 56S1 shows a small growth in Revenue. The Revenue has grown by 7.72% in the last year.
Measured over the past years, 56S1 shows a quite strong growth in Revenue. The Revenue has been growing by 14.05% on average per year.
EPS 1Y (TTM)35.11%
EPS 3Y-22.3%
EPS 5Y4.19%
EPS Q2Q%23.68%
Revenue 1Y (TTM)7.72%
Revenue growth 3Y-1.25%
Revenue growth 5Y14.05%
Sales Q2Q%7.67%
3.2 Future
Based on estimates for the next years, 56S1 will show a very strong growth in Earnings Per Share. The EPS will grow by 22.11% on average per year.
56S1 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.12% yearly.
EPS Next Y29.39%
EPS Next 2Y23.86%
EPS Next 3Y23.06%
EPS Next 5Y22.11%
Revenue Next Year7.45%
Revenue Next 2Y8.04%
Revenue Next 3Y9.07%
Revenue Next 5Y10.12%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 48.24, the valuation of 56S1 can be described as expensive.
Compared to the rest of the industry, the Price/Earnings ratio of 56S1 indicates a rather expensive valuation: 56S1 more expensive than 84.21% of the companies listed in the same industry.
56S1 is valuated expensively when we compare the Price/Earnings ratio to 26.84, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 38.72, the valuation of 56S1 can be described as expensive.
Based on the Price/Forward Earnings ratio, 56S1 is valued expensively inside the industry as 84.21% of the companies are valued cheaper.
The average S&P500 Price/Forward Earnings ratio is at 23.40. 56S1 is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 48.24 | ||
| Fwd PE | 38.72 |
4.2 Price Multiples
89.47% of the companies in the same industry are cheaper than 56S1, based on the Enterprise Value to EBITDA ratio.
56S1's Price/Free Cash Flow ratio is a bit more expensive when compared to the industry. 56S1 is more expensive than 63.16% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 54.03 | ||
| EV/EBITDA | 27.86 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as 56S1's earnings are expected to grow with 23.06% in the coming years.
PEG (NY)1.64
PEG (5Y)11.5
EPS Next 2Y23.86%
EPS Next 3Y23.06%
5. Dividend
5.1 Amount
With a yearly dividend of 0.34%, 56S1 is not a good candidate for dividend investing.
56S1's Dividend Yield is comparable with the industry average which is at 0.60.
With a Dividend Yield of 0.34, 56S1 pays less dividend than the S&P500 average, which is at 2.00.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.34% |
5.2 History
The dividend of 56S1 has a limited annual growth rate of 4.44%.
Dividend Growth(5Y)4.44%
Div Incr Years0
Div Non Decr Years1
5.3 Sustainability
25.41% of the earnings are spent on dividend by 56S1. This is a low number and sustainable payout ratio.
56S1's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP25.41%
EPS Next 2Y23.86%
EPS Next 3Y23.06%
FRA:56S1 (12/29/2025, 7:00:00 PM)
207.9
+1.2 (+0.58%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners11.74%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap20.23B
Revenue(TTM)2.95B
Net Income(TTM)264.10M
Analysts81.11
Price Target240.69 (15.77%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.34% |
Yearly Dividend0.71
Dividend Growth(5Y)4.44%
DP25.41%
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.99%
Min EPS beat(2)-2.24%
Max EPS beat(2)10.22%
EPS beat(4)3
Avg EPS beat(4)9.45%
Min EPS beat(4)-2.24%
Max EPS beat(4)22.18%
EPS beat(8)3
Avg EPS beat(8)-1.58%
EPS beat(12)3
Avg EPS beat(12)-11.08%
EPS beat(16)4
Avg EPS beat(16)-13.1%
Revenue beat(2)1
Avg Revenue beat(2)-1.82%
Min Revenue beat(2)-3.94%
Max Revenue beat(2)0.3%
Revenue beat(4)3
Avg Revenue beat(4)0.7%
Min Revenue beat(4)-3.94%
Max Revenue beat(4)3.52%
Revenue beat(8)5
Avg Revenue beat(8)-0.23%
Revenue beat(12)5
Avg Revenue beat(12)-1.54%
Revenue beat(16)7
Avg Revenue beat(16)-0.72%
PT rev (1m)0.77%
PT rev (3m)0.51%
EPS NQ rev (1m)4.24%
EPS NQ rev (3m)14.4%
EPS NY rev (1m)0.86%
EPS NY rev (3m)1.39%
Revenue NQ rev (1m)-0.08%
Revenue NQ rev (3m)0.03%
Revenue NY rev (1m)-1.38%
Revenue NY rev (3m)-2.76%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 48.24 | ||
| Fwd PE | 38.72 | ||
| P/S | 6.87 | ||
| P/FCF | 54.03 | ||
| P/OCF | 27.7 | ||
| P/B | 5.01 | ||
| P/tB | N/A | ||
| EV/EBITDA | 27.86 |
EPS(TTM)4.31
EY2.07%
EPS(NY)5.37
Fwd EY2.58%
FCF(TTM)3.85
FCFY1.85%
OCF(TTM)7.51
OCFY3.61%
SpS30.27
BVpS41.47
TBVpS-4.02
PEG (NY)1.64
PEG (5Y)11.5
Graham Number63.42
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.35% | ||
| ROE | 6.54% | ||
| ROCE | 7.46% | ||
| ROIC | 5.94% | ||
| ROICexc | 6.26% | ||
| ROICexgc | 21.64% | ||
| OM | 16.63% | ||
| PM (TTM) | 8.96% | ||
| GM | 45.64% | ||
| FCFM | 12.71% |
ROA(3y)7.81%
ROA(5y)9.13%
ROE(3y)17.3%
ROE(5y)20.06%
ROIC(3y)10.41%
ROIC(5y)14.57%
ROICexc(3y)10.84%
ROICexc(5y)15.37%
ROICexgc(3y)26.31%
ROICexgc(5y)36.49%
ROCE(3y)13.07%
ROCE(5y)18.3%
ROICexgc growth 3Y-36.77%
ROICexgc growth 5Y-16.49%
ROICexc growth 3Y-43.34%
ROICexc growth 5Y-25.09%
OM growth 3Y-22.38%
OM growth 5Y-9.98%
PM growth 3Y-24.01%
PM growth 5Y-17.3%
GM growth 3Y-6.9%
GM growth 5Y-3.53%
F-Score8
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 6.84 | ||
| Debt/EBITDA | 2.5 | ||
| Cap/Depr | 113.12% | ||
| Cap/Sales | 12.09% | ||
| Interest Coverage | 3.09 | ||
| Cash Conversion | 90.78% | ||
| Profit Quality | 141.8% | ||
| Current Ratio | 1.05 | ||
| Quick Ratio | 0.5 | ||
| Altman-Z | 4.46 |
F-Score8
WACC9.26%
ROIC/WACC0.64
Cap/Depr(3y)182.98%
Cap/Depr(5y)186.68%
Cap/Sales(3y)13.87%
Cap/Sales(5y)12.23%
Profit Quality(3y)126.76%
Profit Quality(5y)109.63%
High Growth Momentum
Growth
EPS 1Y (TTM)35.11%
EPS 3Y-22.3%
EPS 5Y4.19%
EPS Q2Q%23.68%
EPS Next Y29.39%
EPS Next 2Y23.86%
EPS Next 3Y23.06%
EPS Next 5Y22.11%
Revenue 1Y (TTM)7.72%
Revenue growth 3Y-1.25%
Revenue growth 5Y14.05%
Sales Q2Q%7.67%
Revenue Next Year7.45%
Revenue Next 2Y8.04%
Revenue Next 3Y9.07%
Revenue Next 5Y10.12%
EBIT growth 1Y25.54%
EBIT growth 3Y-23.35%
EBIT growth 5Y2.67%
EBIT Next Year93.64%
EBIT Next 3Y36.06%
EBIT Next 5Y27.7%
FCF growth 1Y219.27%
FCF growth 3Y7.94%
FCF growth 5Y22.24%
OCF growth 1Y15.97%
OCF growth 3Y5.11%
OCF growth 5Y21.32%
SARTORIUS STEDIM BIOTECH / 56S1.DE FAQ
What is the ChartMill fundamental rating of SARTORIUS STEDIM BIOTECH (56S1.DE) stock?
ChartMill assigns a fundamental rating of 4 / 10 to 56S1.DE.
What is the valuation status of SARTORIUS STEDIM BIOTECH (56S1.DE) stock?
ChartMill assigns a valuation rating of 1 / 10 to SARTORIUS STEDIM BIOTECH (56S1.DE). This can be considered as Overvalued.
Can you provide the profitability details for SARTORIUS STEDIM BIOTECH?
SARTORIUS STEDIM BIOTECH (56S1.DE) has a profitability rating of 4 / 10.
What is the financial health of SARTORIUS STEDIM BIOTECH (56S1.DE) stock?
The financial health rating of SARTORIUS STEDIM BIOTECH (56S1.DE) is 4 / 10.
How sustainable is the dividend of SARTORIUS STEDIM BIOTECH (56S1.DE) stock?
The dividend rating of SARTORIUS STEDIM BIOTECH (56S1.DE) is 4 / 10 and the dividend payout ratio is 25.41%.